8-K: Cabaletta Bio Announces Anticipated 2027 BLA Submission for Rese-cel in Myositis Following FDA Alignment

Cabaletta Bio plans to submit a Biologics License Application (BLA) for rese-cel in myositis in 2027 after aligning with the FDA on registrational cohort designs.

Summary

• Cabaletta Bio announced plans for a 2027 BLA submission for rese-cel in myositis following a recent FDA meeting.
• The FDA granted RMAT designation to rese-cel for myositis, a disease affecting approximately 80,000 U.S. patients.
• The company will add two subtype-specific cohorts with approximately 15 patients each to the ongoing RESET-Myositis trial.
• Cabaletta expects to hold registrational discussions with the FDA for SLE and LN in 3Q25 and for systemic sclerosis in 4Q25.
• New clinical data on rese-cel in myositis, SLE/LN, and systemic sclerosis will be presented at the EULAR 2025 Congress in June.
• As of March 31, 2025, Cabaletta had $131.8 million in cash and cash equivalents, expected to fund operations into the first half of 2026.

Sentiment

Score: 7

Explanation: The announcement is generally positive due to the FDA alignment, RMAT designation, and progress in clinical trials. However, the long timeline to BLA submission and cash burn temper the enthusiasm.

Positives

• FDA alignment on registrational cohort design for the RESET-Myositis trial.
• RMAT designation granted by the FDA for rese-cel in myositis, potentially expediting the BLA review process.
• Multiple Phase 1/2 disease cohorts fully enrolled across the RESET clinical development program, with 44 patients enrolled and 23 dosed as of May 9, 2025.
• Cash position of $131.8 million expected to fund operations into the first half of 2026.
• Advancements in manufacturing strategy to reduce costs, increase scale, and shorten vein-to-vein time.

Negatives

• Cash and cash equivalents decreased from $164.0 million as of December 31, 2024, to $131.8 million as of March 31, 2025.
• The BLA submission for rese-cel in myositis is not anticipated until 2027, indicating a relatively long development timeline.

Risks

• The BLA submission is dependent on the success of the registrational study design, which includes two independent, subtype-specific cohorts.
• Clinical trials are subject to risks related to enrollment, safety, and efficacy data.
• Regulatory filings and potential clearance are subject to risks.
• The company's ability to fund its operations and continue as a going concern is a risk.

Future Outlook

Cabaletta anticipates a 2027 BLA submission for rese-cel in myositis and plans to present new clinical data at the EULAR 2025 Congress. The company expects its current cash position to fund operations into the first half of 2026.

Management Comments

• David J. Chang, M.D., Chief Medical Officer of Cabaletta, stated that the clinical safety and efficacy data supported discussions with the FDA and RMAT designation for rese-cel in myositis.
• Management believes that the two registrational cohorts have the potential to support a broad label to address many of the approximately 80,000 myositis patients in the U.S.

Industry Context

Cabaletta Bio is focused on developing targeted cell therapies for autoimmune diseases, an area with significant unmet medical need. The RMAT designation and FDA alignment on trial design are positive steps in advancing rese-cel towards potential approval in myositis, a disease with limited treatment options.

Comparison to Industry Standards

• The current standard of care for myositis typically involves medications to suppress the immune system and/or chronic intensive therapies such as monthly infusions of intravenous immunoglobulin (IVIg).
• IVIg is the only FDA approved therapy for adult DM patients.
• Cabaletta's rese-cel aims to provide a more durable treatment option compared to existing therapies, potentially reducing the need for chronic immunosuppression or IVIg infusions.
• Other companies are also developing cell therapies for autoimmune diseases, but Cabaletta is focusing on targeted approaches with the potential for curative outcomes.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if rese-cel is successfully developed and commercialized.
• Patients: Potential for a new treatment option for myositis and other autoimmune diseases.
• Employees: Continued employment and potential for growth within the company.
• Suppliers and Manufacturing Partners: Continued collaboration and potential for increased business.

Next Steps

• Initiate enrollment in the myositis registrational cohorts in the second half of 2025.
• Present new clinical data at the EULAR 2025 Congress in June.
• Continue advancing BLA-enabling activities for the lentiviral vector process at Oxford Biomedica.
• Implement the planned commercial drug product process at Lonza, expected to come online in early 3Q25.
• Hold registrational discussions with the FDA for SLE and LN in 3Q25 and for systemic sclerosis in 4Q25.
• Submit a BLA for rese-cel in myositis in 2027.

Key Dates

Keywords

rese-cel, myositis, BLA submission, RMAT designation, Cabaletta Bio, autoimmune diseases, clinical trials, FDA, RESET-Myositis, cell therapy